Kidswell Bio Corporation

4584

JP3386460004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-09 EDT			5-day change	1st Jan Change
138 ^JPY	-1.43%		+1.47%	+2.99%

2023	Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc.	CI
2023	Kidswell Bio Corporation announced that it expects to receive Â¥22.8 million in funding from CVI Investments, Inc.	CI

Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc.

July 25, 2023

On July 26, 2023, Kidswell Bio Corporation closed the transaction. The company issued 150,000 common shares at ¥152 per share for gross proceeds of ¥22,800,000.

Latest news about Kidswell Bio Corporation

Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc.	23-07-25	CI
Kidswell Bio Corporation announced that it expects to receive Â¥22.8 million in funding from CVI Investments, Inc.	23-07-09	CI
Kidswell Bio Corporation(TSE:4584) dropped from S&P Global BMI Index	22-09-19	CI
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million	22-05-27	MT
Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody	22-05-27	MT
Kidswell Bio Corporation Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-05	CI
Kidswell Bio Corporation(TSE:4584) added to S&P Global BMI Index	21-09-20	CI
Gene Techno Science Co.,Ltd. Reports Earnings Results for the Year Ended March 2020	20-07-17	CI
Dojin Group Co., Ltd. entered into a share transfer agreement to acquire Advanced Cell Technology and Engineering Ltd. from Gene Techno Science Co.,Ltd. for ¥0.	20-07-09	CI
Gene Techno Science Co.,Ltd. announced that it has received ¥604.852632 million in funding from CVI Investments, Inc.	20-04-07	CI
Gene Techno Science Co.,Ltd. announced that it expects to receive ¥604.852632 million in funding from CVI Investments, Inc.	20-03-22	CI
Gene Techno Science Enters into Research Agreement with Nagoya University	20-03-06	CI
Gene Techno Science Co., Ltd Has Executes A Joint Research Agreement with Oita University	20-03-06	CI
Gene Techno Science Co.,Ltd. acquired remaining 94.7% stake in Japan Regenerative Medicine Co., Ltd. from Noritsu Koki Co., Ltd. for ¥0.	20-02-16	CI
Gene Techno Science Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020	19-11-04	CI
Gene Techno Science Co.,Ltd. Announces Earnings Results for the Six Months Ended September 30, 2019	19-11-04	CI
Gene Techno Science Co.,Ltd. announced that it has received ¥603.495742 million in funding from CVI Investments, Inc.	19-10-15	CI
Gene Techno Science Co.,Ltd. announced that it expects to receive ¥603.495742 million in funding from CVI Investments, Inc.	19-09-29	CI
Gene Techno Science Co., Ltd. and Sanwa Kagaku Kenkyusho Co., Ltd. Announces Manufacturing and Marketing Approval for Darbepoetin Alpha Biosimilars in Japan	19-09-23	CI
Heartseed Inc. announced that it expects to receive funding from Gene Techno Science Co.,Ltd., Nissay Capital Co.,Ltd, SBI Investment Co., Ltd., JMDC Inc., Astellas Venture Management LLC	19-08-29	CI
Gene Techno Science Co.,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-04	CI
Gene Techno Science Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2019	19-05-10	CI
NanoCarrier Co., Ltd. cancelled the acquisition of 5.23% stake in Gene Techno Science Co.,Ltd. from Noritsu Koki Bio Holdings LLC.	19-04-08	CI
Gene Techno Science Co.,Ltd. completed the acquisition of Advanced Cell Technology and Engineering Ltd from Koichi Otomo, Yoshihiko Kitajima, Akira Katayama, Taro Koike, Namiko Shinohara and others.	19-03-31	CI
Gene Techno Science Co.,Ltd. signed a share exchange agreement to acquire Advanced Cell Technology and Engineering Ltd from Koichi Otomo, Yoshihiko Kitajima, Akira Katayama, Taro Koike, Namiko Shinohara and others for ¥5.7 billion.	19-01-16	CI

Chart Kidswell Bio Corporation

Duration

Period

More charts

Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Kidswell Bio Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

140 JPY

Average target price

800 JPY

Spread / Average Target

+471.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KIDSWELL BIO CORPORATION	+2.99%	35.45M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	-2.79%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs